Original Article
Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil
Tania F. Cestaria,
, Cacilda da Silva Souzab, Luna Azulay-Abulafiac, Ricardo Romitid, André V.E. Carvalhoe, Caio César Silva de Castrof, Sílvio Alencar Marquesg, João Roberto Antonioh, Lincoln Fabrícioi, Ahmed M. Solimanj, Tianshuang Wuj, Ranjeeta Sinvhalj, Vassilis Stakiasj, Alexandra P. Songj, Jasmina Kalabick, Naomi Martinj,l, Luiza Keiko Matsuka Oyafusom
a Department of Dermatology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
b Division of Dermatology, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
c Instituto de Dermatologia e Estética do Rio de Janeiro, Rio de Janeiro, Brazil
d Department of Dermatology, Hospital das Clínicas, Universidade de São Paulo, São Paulo, SP, Brazil
e Department of Dermatology, Hospital Moinhos de Vento, Porto Alegre, RS, Brazil
f Discipline of Dermatology, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil
g Department of Infectology, Dermatology, Imaging Diagnosis and Radiotherapy, Faculty of Medicine, Universidade Estadual Paulista, Botucatu, SP, Brazil
h Discipline of Dermatology, Faculdade Estadual de Medicina de São José do Rio Preto, São José do Rio Preto, SP, Brazil
i Dermaology Service, Hospital Universitário Evangélico Mackenzie de Curitiba, Curitiba, PR, Brazil
j AbbVie Inc., North Chicago, Illinois, United States
k AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
l In memoriam
m Department of Dermatology, Faculdade de Medicina de ABC, São Paulo, SP, Brazil
Ver másLido
4183
Vezesque se leu este artigo
1080
Total PDF
3103
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 10 | 250 | 137 | 387 |
| 2025 9 | 243 | 111 | 354 |
| 2025 8 | 217 | 98 | 315 |
| 2025 7 | 252 | 76 | 328 |
| 2025 6 | 240 | 87 | 327 |
| 2025 5 | 441 | 88 | 529 |
| 2025 4 | 625 | 126 | 751 |
| 2025 3 | 461 | 89 | 550 |
| 2025 2 | 117 | 82 | 199 |
| 2025 1 | 148 | 94 | 242 |
| 2024 12 | 109 | 92 | 201 |
